Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. (Q38340085)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25641072 AND SRC:MED&resulttype=core&format=json

29 February 2020

review article

1 reference

title

Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25641072 AND SRC:MED&resulttype=core&format=json

29 February 2020

0 references

1 reference

ChEBI release 2020-05-28

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25641072 AND SRC:MED&resulttype=core&format=json

29 February 2020

Gianluca Ianiro

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25641072 AND SRC:MED&resulttype=core&format=json

29 February 2020

Rosario Landi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25641072 AND SRC:MED&resulttype=core&format=json

29 February 2020

Franco Scaldaferri

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25641072 AND SRC:MED&resulttype=core&format=json

29 February 2020

Eleonora Gaetani

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25641072 AND SRC:MED&resulttype=core&format=json

29 February 2020

9

Antonio Gasbarrini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25641072 AND SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Iolanda Scoleri

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25641072 AND SRC:MED&resulttype=core&format=json

29 February 2020

Giovanni Bruno

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25641072 AND SRC:MED&resulttype=core&format=json

29 February 2020

Mariachiara Campanale

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25641072 AND SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

English

0 references

publication date

1 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25641072 AND SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25641072 AND SRC:MED&resulttype=core&format=json

29 February 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25641072 AND SRC:MED&resulttype=core&format=json

29 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25641072 AND SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

607-615

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25641072 AND SRC:MED&resulttype=core&format=json

Functional bowel disorders

29 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

The gut microbiota--masters of host development and physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Linking the gut microbiota to human health

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Biopsychosocial model of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Crosstalk at the mucosal border: importance of the gut microenvironment in IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Use and abuse of hydrogen breath tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Postinfectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Postinfectious irritable bowel syndrome--a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Irritable Bowel Syndrome and Small Intestinal Bacterial Overgrowth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Intestinal microbiota and its role in irritable bowel syndrome (IBS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Rifaximin pharmacology and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Host responses to the human microbiome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Alterations in the intestinal microbiota and functional bowel symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Effects of Rifaximin Treatment and Retreatment in Nonconstipated IBS Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Bile acids improve the antimicrobial effect of rifaximin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

In vitro activity and fecal concentration of rifaximin after oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Rifaximin for the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Systemic pharmacokinetics of rifaximin in volunteers with shigellosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Irritable bowel syndrome in psychiatric perspectives: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Irritable bowel syndrome and dysthymia. Is there a relationship?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Rifaximin is a gut-specific human pregnane X receptor activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Probable Interaction Between Warfarin and Rifaximin in a Patient Treated for Small Intestine Bacterial Overgrowth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Relevant role of efflux pumps in high levels of rifaximin resistance in Escherichia coli clinical isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2015.1007951

10.1517/14656566.2015.1007951

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25641072 AND SRC:MED&resulttype=core&format=json

29 February 2020

1 reference